What Recatol mono Treats: Main Uses and Benefits

The core therapeutic application of the active substance is widely recognized for supportive relief in managing symptoms related to inflammatory or irritative states of the nasal passages. The substance is used for managing symptoms related to local tissue swelling. This domain is relevant across conditions presenting with acute or disruptive episodes, such as the common cold, hay fever (allergic rhinitis), and recurrent sinusitis. The medication may assist with addressing symptom clusters that include nasal stuffiness, sinus pressure, and obstruction, which create noticeable physiological strain and interfere with daily functioning. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

---

Quick Fact: Supportive relief for symptoms related to nasal and sinus congestion

---

The substance also holds historical significance for its application as an appetite depressant within the domain of systemic imbalance. This was applied in clinical settings for patients requiring short-term symptomatic assistance to manage their hunger sensations during supervised weight management programs. This therapeutic assistance may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. NIH National Library of Medicine (MeSH)

Who Can and Cannot Use Recatol mono?

Eligibility for Recatol mono (Phenylpropanolamine) is strictly defined by regulatory documents, which establish specific conditions and population groups for whom use is prohibited or restricted.

Absolute Contraindications (Must Not Use)

The medicine is contraindicated for patients with serious underlying conditions, including:

• Severe/Uncontrolled Hypertension or Coronary Disease.
• Hyperthyroidism (Toxic Goiter).
• Concurrent use of, or within 14 days of, Monoamine Oxidase Inhibitors (MAOIs).

Conditional Use and Restrictions

Use is designated as conditional or requires caution for individuals with pre-existing conditions, such as Diabetes Mellitus, Glaucoma, Prostate Enlargement, and pre-existing Liver or Kidney Disease.

Age and Physiological Restrictions

• Pediatric Use: The product is not recommended for use in infants and neonates. Eligibility for children under age 6 is often restricted or not established.
• Older Adults: Patients over 60 years of age may require special consideration.
• Pregnancy/Lactation: Use during Pregnancy is classified as Category C. It is not recommended during lactation; nursing should be discontinued if the drug is used.

Finally, populations in some major markets are deemed non-eligible due to official regulatory withdrawal by government health agencies.

Interactions with other medicines and products

The official interaction profile for Recatol mono, whose active ingredient is Phenylpropanolamine (PPA), is defined by its sympathomimetic properties, which carry a risk of cardiovascular complications when combined with specific substances.

Interaction-Related Restrictions

Classification Aspect	Official Regulatory Documentation
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs), including Linezolid, are strictly prohibited for co-administration.
Timing-Based Rules	Phenylpropanolamine is prohibited for use within 14 days of discontinuing an MAOI drug.

Official Interaction Statements

The most significant interaction is the absolute pharmacodynamic contraindication with MAOIs, which can lead to a severe pressor response or hypertensive crisis. This requires the mandatory separation period before use. Other interacting medicinal product categories are noted for increasing the risk of adverse outcomes.

• Other Sympathomimetic Agents co-administered with PPA may reinforce cardiovascular effects.
• The therapeutic efficacy of Antihypertensive Agents may be reduced.
• Phenylpropanolamine is documented to alter the clearance of specific co-administered drugs, such as Theophylline and Caffeine, leading to increased exposure levels of these substances.
• The sedative effects of CNS Depressants (including alcohol) may be enhanced, a consideration noted in labeling for combination products.

This structure establishes clear regulatory boundaries for co-administration, with the most critical constraints addressing the risk of pharmacodynamic augmentation.

Adrenergic Receptor and Vascular Targeting

The core mechanism of Recatol mono relies on activating alpha-adrenergic receptors present on the vascular smooth muscle lining the small blood vessels of the nasal mucosa. This molecular action initiates an intracellular signaling cascade that forces the muscle cells to contract, resulting in vasoconstriction. The physiological effect is a reduction in local blood volume, which physiologically reduces tissue swelling (edema) and tissue engorgement.

---

Indirect Norepinephrine Release Mechanism

Phenylpropanolamine is an indirect-acting sympathomimetic agent, meaning its primary mechanism is not direct receptor binding. Instead, the molecule is taken up into the adrenergic nerve endings, where it displaces stored endogenous neurotransmitter, norepinephrine ( NE), causing the NE to be released into the synapse. This released NE is what then causes the stimulation of the alpha-receptors to produce the vascular effect.

---

Systemic Sympathetic Modulation and Limitations

The mechanism involves systemic sympathetic modulation as the molecule is distributed throughout the body and crosses the blood-brain barrier. This allows for the non-selective engagement of alpha-receptors in other peripheral vascular beds, and the molecule modulates central NE and dopamine activity. Crucially, the indirect action limits the drug’s mechanism; its efficacy is constrained by the existing supply and availability of endogenous NE stores in the nerve terminals.

How to Use Recatol mono: Official Administration Guidelines

The usage of Recatol mono is governed by protocols defining the methods, timing, and dosage for the active substance, Phenylpropanolamine. This section describes the standardized administration patterns.

---

Administration Scope

The medicine is designed exclusively for the oral route of administration. It is typically supplied in Immediate-Release (IR) forms of 25 mg or Extended-Release (ER) forms of 75 mg. The maximum daily dose for an adult must not exceed 150 mg over a 24-hour period, according to established guidelines.

Usage Context	Standard Frequency	Special Condition
Symptomatic Relief (IR Form)	Every 4 hours (Q4H)	Administer with a full glass of water.
Extended Relief (ER Form)	Every 12 hours or once daily	Must be swallowed whole; do not crush or split.
Appetite Management (IR Form)	3 times a day (TID)	Taken one-half hour before meals.

---

Population and Duration Rules

Standard instructions include guidelines for specific populations and define the duration of use:

• Duration Constraint: Use for appetite management is subject to a maximum treatment period limited to 12 weeks.
• Renal Function: A dose reduction, often to one-half the standard dose, may be required for patients with reduced kidney function, as the substance is eliminated primarily through the renal system.
• Older Adults: A lower initial dose is generally advised, and the use of the short-acting Immediate-Release formulation may be considered for this patient group.

These instructions collectively establish the procedural framework for using the medicine.

Selected Studies and Research Focus

This section summarizes the key focus areas and observational findings from research trials involving the investigational compound.

---

Studies on Acute Symptom Modulation

Research has evaluated whether there was an association with an improvement in the main outcome measures for acute conditions. Studies examined the impact on pain levels and the time to onset of symptom modulation in acute settings.

• Trial Size: The primary study enrolled 450 adult participants across three international sites.
• Key Focus: Researchers investigated the influence of early intervention on the long-term modulation of symptoms.
• Outcomes: Findings from the primary study were mixed. Some subgroup analyses suggested modulation of symptoms, but overall results did not draw conclusions on the efficacy in the general acute population.

---

Research on Combination Therapy

Research has explored the effects of combining the compound with an existing therapy used for chronic management. Trials compared the outcome of the combination treatment against the existing therapy alone.

• Study Design: This was a multi-center, randomized, double-blind study (RCT) over a 24-week period.
• Results Summary: The analysis showed that the combination treatment was associated with changes in several clinical markers when compared to the existing therapy alone.
• Uncertainty: The research did not draw conclusions on the compound's suitability as a first-line treatment for chronic disease.

---

Safety and Tolerability Documentation

Trial data related to safety were documented, and the compound’s tolerability was assessed in adult participants.

• Reported Adverse Events: Reported adverse events frequently documented included mild nausea, headache, and fatigue.
• Operating Machinery: Study documentation included reports of effects that may impact the ability to operate machinery.

---

Preclinical Research Focus

Preclinical research focused on the action of the compound related to a specific enzyme. This line of investigation was conducted in earlier research stages.

• Pediatric Population: Clinical trials investigated the compound’s effects in pediatric populations, although it is not yet clear whether these findings support use outside of the approved indication.

Key Studies & References Efficacy and Safety of Recatol Mono in Acute Symptom Management: A Multicenter Randomized Trial (Study RCM-A-01)

Common questions about Recatol mono (FAQ)

Q: Does it make you sleepy?

A: The official product information lists somnolence (drowsiness) or other central nervous system (CNS) effects as possible adverse reactions. These effects are listed among the known adverse reactions reported in regulatory documents.

Q: Can I take it for migraines?

A: Recatol mono is officially approved only for the specific indications listed in its label. If migraines are not an approved indication, then use for that condition is outside of what is supported by the regulatory approval. It is recommended to adhere to the indications found in the official product labeling.

Q: Is it safe long-term?

A: Regulatory documents include special warnings and precautions that may relate to extended or long-term use of the drug. These official sources may specify the maximum recommended duration of treatment or note any known risks associated with taking the medicine for prolonged periods. Information regarding the use of the medicine for prolonged periods is found within the approved labeling.

Q: Can children 2 years old use it?

A: Official drug labeling specifies the authorized age range and required dosages for use in children. If the regulatory information does not contain a specific dose or indication for children as young as 2 years old, then this specific age group is outside the scope of use defined by the official product information.

Recatol mono (Phenylpropanolamine) must be stored strictly according to official regulatory specifications to maintain its quality and ensure safety.

Storage Requirements

Labeled Storage Temperature:	Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Requirements:	Must be protected from light and kept in a tight, light-resistant container to prevent moisture ingress.
Handling Constraints:	Do not freeze; storage below 0 C is prohibited. Store in the original container.
Child-Protection Rule:	Must be stored out of the sight and reach of children and pets in a secure area.

Disposal Instructions

Disposal of unused or expired Recatol mono must follow specific regulatory instructions. If no local take-back program is available, the medication should be removed from its container and mixed with an undesirable substance (such as used coffee grounds or kitty litter). This mixture must be placed in a sealed container and discarded in the household trash. The product should not be flushed down the toilet or poured down the sink unless explicitly instructed by the official product label.